Johan Harmenberg has reached retirement age and as the company continues to expand its activities he has decided to step down as CMO but continue to work as a member of the company’s medical team.

Klaas Bakker has been appointed as the new Chief Medical Officer (CMO) for Oncopeptides, starting in November.

From 2015 to present Klaas has worked at AstraZeneca in different roles with increasing responsibility and seniority, most recently as VP Medical for their Tagrisso -TDR Franchise with global responsibility. Klaas holds an MD and is a board certified neurosurgeon from the University of Groningen, the Netherlands, and was clinically active at the Groningen University Hospital until 2015. He also helds a PhD in immuno-hematology and has authored over 40 publications in international peer-reviewed journals.

“Johan will continue to work as a valued member of our medical team which is important as he has extensive experience and knowledge about melflufen as well as our network of clinicians. I am very pleased that we have been able to attract Klaas to take over as Chief Medical Officer with his global outlook and experience from oncology products in the market as we are rapidly moving towards a potential market authorisation. We welcome Klaas to Oncopeptide’s management team and look forward to working together,” says Jakob Lindberg, CEO of Oncopeptides.

Photo of Johan Harmenberg: Oncopeptides